The Vitreous Body: Structure and Function

The vitreous body accounts for roughly 80% of the eye's total volume — a fact that tends to surprise people who think of it as just filler. It is not filler. It is a precisely organized, biochemically active gel that sits between the lens and the retina, and when it fails — through liquefaction, detachment, or hemorrhage — the consequences range from annoying floaters to permanent vision loss. Understanding its structure helps explain why.

What the Vitreous Body Actually Is

The vitreous body (also called the vitreous humor) is a transparent, avascular gel occupying the posterior segment of the eye. In adult humans, it has a volume of approximately 4 milliliters (National Eye Institute). Unlike aqueous humor, which circulates and refreshes continuously, the vitreous is largely static. What the eye produces at birth is, more or less, what it works with for life — which makes its eventual breakdown with age a one-way street.

The gel is composed of roughly 98–99% water, yet it maintains a structured, semi-solid consistency. That paradox is resolved when you examine the remaining 1–2%: a scaffolding of collagen fibrils (predominantly type II and type IX) interwoven with hyaluronic acid, a glycosaminoglycan capable of binding extraordinary amounts of water relative to its own molecular weight. This collagen-hyaluronate matrix is what holds the water in place and gives the vitreous its characteristic transparency and elasticity.

Anatomical Zones and Attachments

The vitreous is not a uniform blob. Anatomists distinguish at least three structural regions:

The firmest vitreoretinal attachment is at the vitreous base. This matters clinically: when the vitreous separates from the retina during posterior vitreous detachment (PVD), it peels away everywhere except the base, which can generate enough traction to tear the peripheral retina. The Weiss ring — a circular opacity visible on ophthalmoscopy after PVD — is the peripapillary glial tissue that detaches from around the optic disc and floats forward into the visual axis.

The Collagen-Hyaluronate Matrix: Why It Works, and Why It Fails

Hyaluronic acid in the vitreous was characterized in detail by Balazs and colleagues, work that eventually laid the groundwork for ophthalmic viscoelastic devices used in cataract surgery. Hyaluronic acid molecules in the vitreous can reach molecular weights exceeding 2–4 million Daltons (University of Michigan Kellogg Eye Center educational resources). At that size, each molecule occupies an enormous domain in solution, creating a hydrated meshwork that keeps the collagen fibrils separated, prevents them from aggregating, and maintains optical clarity.

With age, however, hyaluronic acid concentration decreases and collagen fibrils progressively aggregate into visible strands. The gel liquefies — a process called syneresis — forming liquid pockets while collapsed collagen bundles drift through them. This is the structural origin of floaters. By the seventh decade of life, approximately 63% of people have experienced some degree of vitreous liquefaction (Sebag J., Graefe's Archive for Clinical and Experimental Ophthalmology), a figure that climbs further with myopia, uveitis, or prior ocular trauma.

Functional Roles

The vitreous is not merely a structural spacer, though it does that job effectively — maintaining the eye's spherical shape and holding the retina in gentle apposition to the retinal pigment epithelium. Its functional contributions include:

Optical clarity. The gel's organized matrix scatters less than 1% of incident light under normal conditions. The collagen fibril diameter (~10–15 nm) and spacing are below the wavelength of visible light, which is what makes the vitreous transparent rather than cloudy (Vit-Buckley, Experimental Eye Research).

Metabolic buffering. The vitreous acts as a reservoir and diffusion barrier for oxygen, glucose, ascorbic acid, and growth factors — modulating what reaches the retina and lens. Ascorbate concentration in the vitreous is notably high, roughly 1–2 mM, thought to neutralize reactive oxygen species and protect the avascular lens.

Mechanical protection. The gel dampens sudden intraocular pressure changes and absorbs mechanical shocks, reducing stress on the delicate neuroretina.

Developmental scaffolding. During fetal development, the primary vitreous contains a vascular structure called the hyaloid artery, which supplies the developing lens. This vessel regresses completely before birth in healthy eyes; failure to regress results in persistent fetal vasculature (PFV), a cause of pediatric vision impairment.

Clinical Relevance

Vitreous pathology connects directly to some of ophthalmology's highest-stakes diagnoses. Vitreous hemorrhage — blood entering the gel, typically from diabetic neovascularization or retinal tears — blocks light transmission and can obscure the retina from examination entirely. Tractional forces from an anomalous PVD can cause macular holes, epiretinal membranes, or rhegmatogenous retinal detachment. Pharmacologic vitreolysis using ocriplasmin (a recombinant protease targeting fibronectin and laminin at the vitreoretinal interface) was FDA-approved in 2012 specifically to address symptomatic vitreomacular adhesion — a recognition that the vitreoretinal junction is a therapeutic target, not just an anatomical curiosity.

Understanding the vitreous body is, ultimately, understanding what stands between the retina and the outside world — not a passive background structure, but an organized, aging, occasionally unruly partner in the act of seeing.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)